Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36


Therapeutic Targeting of Telomerase.

Jäger K, Walter M.

Genes (Basel). 2016 Jul 21;7(7). pii: E39. doi: 10.3390/genes7070039. Review.


Telomere and Telomerase Therapeutics in Cancer.

Xu Y, Goldkorn A.

Genes (Basel). 2016 May 26;7(6). pii: E22. doi: 10.3390/genes7060022. Review.


Overexpressed oncogenic tumor-self antigens.

Bright RK, Bright JD, Byrne JA.

Hum Vaccin Immunother. 2014;10(11):3297-305. doi: 10.4161/hv.29475. Review.


Recent advances in the development of breast cancer vaccines.

Milani A, Sangiolo D, Aglietta M, Valabrega G.

Breast Cancer (Dove Med Press). 2014 Oct 14;6:159-68. doi: 10.2147/BCTT.S38428. Review.


Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY, Weiner DB.

Cancer Immunol Res. 2013 Sep;1(3):179-89. doi: 10.1158/2326-6066.CIR-13-0001.


Trial Watch: Peptide vaccines in cancer therapy.

Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Dec 1;2(12):e26621. Review.


miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase.

Chen L, Lü MH, Zhang D, Hao NB, Fan YH, Wu YY, Wang SM, Xie R, Fang DC, Zhang H, Hu CJ, Yang SM.

Cell Death Dis. 2014 Jan 30;5:e1034. doi: 10.1038/cddis.2013.553.


Progress in the development of a therapeutic vaccine for breast cancer.

Coveler AL, Bates NE, Disis ML.

Breast Cancer (Dove Med Press). 2010 Jun 4;2:25-36. Review.


Clinical implications of antitelomeric drugs with respect to the nontelomeric functions of telomerase in cancer.

Roh JI, Sung YH, Lee HW.

Onco Targets Ther. 2013 Aug 26;6:1161-6. doi: 10.2147/OTT.S50918. Review.


Tumor-associated antigens in breast cancer.

Criscitiello C.

Breast Care (Basel). 2012 Aug;7(4):262-6. doi: 10.1159/000342164.


Trial watch: Dendritic cell-based interventions for cancer therapy.

Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Oct 1;1(7):1111-1134.


Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.

Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G.

Oncoimmunology. 2012 Aug 1;1(5):670-686.


Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.

Gong HX, He L, Li XP, Wang YD, Li Y, Huang JJ, Wang Z, Xie D, Kung HF, Peng Y.

Oncol Rep. 2012 Apr;27(4):1163-9. doi: 10.3892/or.2011.1619.


Is telomerase a viable target in cancer?

Buseman CM, Wright WE, Shay JW.

Mutat Res. 2012 Feb 1;730(1-2):90-7. doi: 10.1016/j.mrfmmm.2011.07.006. Review.


Dendritic cell-based immunotherapy for prostate cancer.

Jähnisch H, Füssel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber EP, Wirth MP, Schmitz M.

Clin Dev Immunol. 2010;2010:517493. doi: 10.1155/2010/517493. Review.


Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B.

J Oncol. 2011;2011:941876. doi: 10.1155/2011/941876.


T-cell-based therapies for malignancy and infection in childhood.

Ahmed N, Heslop HE, Mackall CL.

Pediatr Clin North Am. 2010 Feb;57(1):83-96. doi: 10.1016/j.pcl.2009.11.002. Review.


Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.

Schreiber TH, Raez L, Rosenblatt JD, Podack ER.

Semin Immunol. 2010 Jun;22(3):105-12. doi: 10.1016/j.smim.2010.02.001. Review.


Clinical applications of a peptide-based vaccine for glioblastoma.

Kanaly CW, Ding D, Heimberger AB, Sampson JH.

Neurosurg Clin N Am. 2010 Jan;21(1):95-109. doi: 10.1016/ Review.


Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M, Howard J, Paisley J, Boeglin D, Ratliff TL, Williams RD.

Clin Cancer Res. 2009 Dec 1;15(23):7375-80. doi: 10.1158/1078-0432.CCR-09-1910.

Supplemental Content

Support Center